AR055615A1 - Dispersiones amorfas solidas - Google Patents

Dispersiones amorfas solidas

Info

Publication number
AR055615A1
AR055615A1 ARP060103739A ARP060103739A AR055615A1 AR 055615 A1 AR055615 A1 AR 055615A1 AR P060103739 A ARP060103739 A AR P060103739A AR P060103739 A ARP060103739 A AR P060103739A AR 055615 A1 AR055615 A1 AR 055615A1
Authority
AR
Argentina
Prior art keywords
solid
amorph
dispersions
pyridazino
acetamide
Prior art date
Application number
ARP060103739A
Other languages
English (en)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499538&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of AR055615A1 publication Critical patent/AR055615A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se describen formulaciones de dispersiones solidas amorfas que comprenden 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida.
ARP060103739A 2005-08-29 2006-08-28 Dispersiones amorfas solidas AR055615A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71215005P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
AR055615A1 true AR055615A1 (es) 2007-08-29

Family

ID=37499538

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103739A AR055615A1 (es) 2005-08-29 2006-08-28 Dispersiones amorfas solidas

Country Status (31)

Country Link
US (1) US7713548B2 (es)
EP (1) EP1926476B1 (es)
JP (1) JP5026426B2 (es)
KR (1) KR20080061354A (es)
CN (1) CN101272767B (es)
AR (1) AR055615A1 (es)
AU (1) AU2006285111B8 (es)
BR (1) BRPI0615609A2 (es)
CA (1) CA2619438A1 (es)
CR (1) CR9750A (es)
DK (1) DK1926476T3 (es)
EA (1) EA015715B1 (es)
EC (1) ECSP088203A (es)
ES (1) ES2414434T3 (es)
HK (1) HK1124785A1 (es)
HN (1) HN2008000360A (es)
HR (1) HRP20130533T1 (es)
IL (1) IL189587A (es)
MA (1) MA29783B1 (es)
ME (1) ME01560B (es)
NO (1) NO20081364L (es)
NZ (1) NZ566313A (es)
PL (1) PL1926476T3 (es)
PT (1) PT1926476E (es)
RS (1) RS52914B (es)
SI (1) SI1926476T1 (es)
TN (1) TNSN08069A1 (es)
TW (1) TWI398250B (es)
UA (1) UA93517C2 (es)
WO (1) WO2007027494A2 (es)
ZA (1) ZA200801893B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3091011T3 (en) 2006-04-07 2018-02-26 Vertex Pharma MODULATORS OF ATP BINDING CASSETTE TRANSPORT
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
JP2011513497A (ja) * 2008-03-11 2011-04-28 ドクター・レディーズ・ラボラトリーズ・リミテッド レナリドミドの調製
MX2011001474A (es) * 2008-08-18 2011-03-25 Sanofi Aventis Llc Proceso para preparar polimorfos.
PL3835297T3 (pl) * 2010-03-25 2023-09-11 Vertex Pharmaceuticals Incorporated Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2822539B1 (en) 2012-03-07 2018-11-21 National Institute Of Pharmaceutical Education And Research (NIPER) Nanocrystalline solid dispersion compositions
KR101986683B1 (ko) 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
EP3039599A4 (en) * 2013-08-30 2017-04-19 Hewlett-Packard Enterprise Development LP Comparing real-time movements to pattern profile background
EP3120871B1 (en) * 2014-03-18 2023-06-28 Takeda Pharmaceutical Company Limited Solid dispersion
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CA3236518A1 (en) 2016-02-29 2017-09-08 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
MX2019015612A (es) * 2017-07-04 2020-02-26 Jiangsu Hengrui Medicine Co Composicion farmaceutica y metodo para preparar el mismo.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
FR2829939B3 (fr) * 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
HN2008000360A (es) 2011-05-31
ES2414434T3 (es) 2013-07-19
BRPI0615609A2 (pt) 2011-05-24
EA015715B1 (ru) 2011-10-31
SI1926476T1 (sl) 2013-07-31
IL189587A (en) 2012-12-31
IL189587A0 (en) 2008-08-07
CN101272767A (zh) 2008-09-24
HRP20130533T1 (en) 2013-07-31
RS52914B (en) 2014-02-28
TW200727902A (en) 2007-08-01
CN101272767B (zh) 2012-08-29
TWI398250B (zh) 2013-06-11
EA200800713A1 (ru) 2008-10-30
TNSN08069A1 (en) 2009-07-14
PT1926476E (pt) 2013-07-10
UA93517C2 (en) 2011-02-25
NZ566313A (en) 2011-04-29
EP1926476B1 (en) 2013-04-10
US7713548B2 (en) 2010-05-11
JP5026426B2 (ja) 2012-09-12
AU2006285111B8 (en) 2012-05-17
EP1926476A2 (en) 2008-06-04
WO2007027494A3 (en) 2007-08-02
PL1926476T3 (pl) 2013-08-30
CA2619438A1 (en) 2007-03-08
KR20080061354A (ko) 2008-07-02
US20080160080A1 (en) 2008-07-03
WO2007027494A2 (en) 2007-03-08
AU2006285111B2 (en) 2012-04-26
HK1124785A1 (es) 2009-07-24
JP2009506114A (ja) 2009-02-12
ZA200801893B (en) 2009-08-26
ME01560B (me) 2014-04-20
CR9750A (es) 2008-06-18
NO20081364L (no) 2008-04-03
MA29783B1 (fr) 2008-09-01
ECSP088203A (es) 2008-06-30
DK1926476T3 (da) 2013-07-01
AU2006285111A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
AR055615A1 (es) Dispersiones amorfas solidas
EA200701918A1 (ru) Белок липокалин
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
TW200715634A (en) Stable organic devices
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
HN2005029978A (es) Formulaciones
TW200700406A (en) Novel thiophene derivatives
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
UY3402Q (es) Diseno de tractor
TW200716552A (en) Novel thiophene derivatives
TW200738670A (en) Novel thiophene derivatives
WO2007081878A8 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
AR054937A1 (es) Goma de mascar biodegradable
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
MY150643A (en) Methods and compositions for targeting hepsin
MY139010A (en) 6-azo-5, 5'-dihydroxy -7,7'-disulfo-2-2'-dinaphthylamine derivatives
CY1114124T1 (el) Αμορφες στερεες διασπορες της 7-χλωρο-ν,ν,5-τριμεθυλ-4-οξο-3-φαινυλ-3,5- διϋδρο-4η-πυριδαζινο[4,5-β]ινδολη-1-ακεταμιδης
어린 et al. COpyright (C) 2005 NuriMedia Co., Ltd.
UY34598A (es) Antranilamidas insecticidas
BRPI0401530B1 (pt) fertilizadora de uso combinado.
AU2005900833A0 (en) P.K.'s Quarterball
ATE434604T1 (de) Amorphes tamsulosin-hydrochlorid

Legal Events

Date Code Title Description
FA Abandonment or withdrawal